2113results about "Drug compositions" patented technology

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

Compounds having the structure of Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof; wherein R1, R2, R3, R4, R5, L1, L2, a and z are as defined herein, are disclosed. Use of these compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds, and methods for their use and preparation are also provided.

Provided herein, inter alia, is an engineered non-plant cell that produces a hyoscyamine alkaloid product, a precursor of a hyoscyamine alkaloid product, or a derivative of a hyoscyamine alkaloid product. Also described is a method for producing a scopolamine alkaloid, a precursor of a scopolamine alkaloid product, or a derivative of a scopolamine alkaloid product using a cell.

The invention discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition of the present invention comprises an acidic secretory protein rich in cysteine, a disaccharide chain proteoglycan, and an XV-type collagen alpha1 chain. The biological material system loaded with the three types of proteins can promote angiogenesis, and can improve the tissue regeneration efficiency of bone, cartilage and skin defect areas.

To provide a simple method for producing a fluorinated pyrimidone compound that offers potential for diverse derivatization as an intermediate for pharmaceuticals or agrochemicals.SOLUTION: A method for producing a fluorinated pyrimidone compound comprises a step of preparing a fluorinated pyrimidone compound represented by general formula (3) through the reaction of a hexafluoroisobutyric acid ester represented by general formula (1) with an amidinopyridine represented by general formula (2).SELECTED DRAWING: None

The invention relates to the technical field of RNA interference, and particularly discloses an RNA interference fragment of a crustacean hyperglycemia hormone gene and application of the RNA interference fragment. The RNA interference fragment provided by the invention is injected into a third step foot of a river crab in an injection manner and is used for interfering the mRNA expression quantity of a hyperglycemia hormone gene CHH of a crustacean of the river crab. The fighting behavior of the eriocheir sinensis is effectively controlled, the yield in large-scale breeding of the eriocheir sinensis is improved, and economic losses caused by incomplete crabs due to fighting of the eriocheir sinensis are reduced.

Disclosed herein are a peptoid compound and a peptoid conjugate such as a peptoid-lipid conjugate, and preparation methods therefor and the use thereof in a small molecule drug and nucleic acid delivery. Further disclosed herein are a lipid particle containing the peptoid-lipid conjugate, such as a liposome and a lipid nanoparticle, and a small molecule drug and / or a nucleic acid delivery composition containing the peptoid-lipid conjugate or the lipid particle. The peptoid-lipid conjugate, lipid particle, and small molecule drug and / or nucleic acid delivery composition that can be used for the small molecule drug and nucleic acid delivery of the present invention enable highly efficient compounding, protection, intracellular and targeted delivery and release of the small molecule drug and biomolecules, such as nucleic acids, in tissues and organs both in vitro and in vivo.

The invention relates to the technical field of genetic engineering, in particular to recombinant humanized collagen and a preparation method thereof. The recombinant humanized III-type collagen provided by the invention can be efficiently and stably expressed under three expression systems of yeast, escherichia coli and CHO cells, and has biological activity superior to that of commercially available collagen products. The recombinant humanized III-type collagen disclosed by the invention has structural characteristics and functional activity similar to those of natural collagen, so that the recombinant humanized III-type collagen has wide application prospects in the aspects of biomedical materials, tissue engineering products, cosmetics, foods, health care products or medicines, medical instruments, medical cosmetology and the like.

A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.

To provide a novel autophagy derivative.SOLUTION: The autophagy derivative contains Equisetum arvense L. and / or Ligustrum Lucidum Aiton.SELECTED DRAWING: None

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.

The invention belongs to the technical field of health-care food, and particularly relates to a medicinal and edible tea substitute beverage for relieving summer-heat and resolving dampness as well as a preparation method and application thereof, and the medicinal and edible tea substitute beverage is prepared from the following raw materials in parts by weight: 3-20 parts of agastache rugosus, 2-20 parts of elsholtzia, 5-30 parts of codonopsis pilosula and 1-15 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition adopts a traditional Chinese medicine syndrome differentiation and treatment method to dispel summer heat, relieve exterior syndrome, resolve dampness with aromatics, regulate qi and strengthen the middle warmer, and can well improve or relieve the heatstroke symptom of subjects.

Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric Fc-containing proteins are provided.

The present invention relates to a composition comprising a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a surfactant. [wherein R1, P1, R2, P3, P4, R5, P6, R10, P10 and P11 are C1 to C6 alkyl or the like; R3 and P9 are hydrogen or the like; R7 is phenethyl optionally substituted by halogen or the like; R8 forms a 4-to 7-membered saturated heterocyclic ring together with a carbon atom bonded to P8 and R8 and a nitrogen atom bonded to P8; R9 forms a 3- to 8-membered alicyclic ring together with Q9 and a carbon atom bonded to R9 and Q9; and R11 is di-C1 to C6 alkylaminocarbonyl or the like].

The present invention relates to compositions for in vitro and in vivo delivery of nucleic acids, in particular messenger RNAs (mRNAs), into a target cell and their applications. The present invention is directed to a composition comprising (A) at least one nucleic acid and (B) at least one lipid nanoparticle (LNP) comprising (i) at least one ionizable lipid; (ii) at least one phospholipid; (iii) at least one sterol, especially neutral sterol; (iv) at least one poly(ethyleneglycol)-lipid (PEG-lipid); and (v) an imidazolium-based cationic lipid of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9, Y and A− are as defined in the description. The present invention also relates to a method for in vitro or in vivo transfection of live cells and uses of said composition.

The present invention relates to inhibitors of CD248, pharmaceutical compositions containing said inhibitors, and uses thereof. In particular, the invention relates to antibodies or antigen binding fragments thereof that bind specifically to human CD248 and have an anti-fibrotic effect.

The present invention relates to methods for producing a preparation comprising recombinant AAV (rAAV), such methods comprising a step of mechanical lysis on mammalian producer cells, and methods for increasing the viral genome titre and / or capsid titre of a preparation comprising recombinant adeno-associated virus, related uses, and preparations obtained by or obtainable by the methods.

Methods for stereo-selectively crystallizing 3-keto-5β-cholanic acid ("3-KCA") and 3-keto ursodeoxycholic acid ("3-KUDCA") of exceptional purity, salts useful in carrying out such methods, particularly the t-butylamine and cyclohexylamine salts of 3-KCA, the t-butylamine salt of 3-KUDCA, and crystalline forms of such salts, and methods of making commercial steroids from such purified materials.

The invention discloses a self-heating ginger-separated moxibustion patch which is mainly composed of a skin-friendly cloth applying layer, an iron powder heating layer, a traditional Chinese medicine combination layer, a ginger-separated synergistic layer and a release paper layer, and the skin-friendly cloth applying layer, the iron powder heating layer, the traditional Chinese medicine combination layer, the ginger-separated synergistic layer and the release paper layer are sequentially arranged from top to bottom. The iron powder heating layer is located in the middle of the skin-friendly compress layer, the traditional Chinese medicine combination layer is located on the surface of the iron powder heating layer, and the ginger separation synergistic layer is located in the middle of the traditional Chinese medicine combination layer. According to the self-heating moxibustion patch, the defect that the efficacy of an existing self-heating moxibustion patch is insufficient due to low temperature is overcome, and the user body feeling of the self-heating moxibustion patch is improved; according to the self-heating moxibustion patch, the defect that the effect of ginger moxibustion cannot be fully exerted in a component adding mode in an existing moxibustion patch is overcome, and traditional Chinese medicine components in the self-heating moxibustion patch can be better exerted.

The invention discloses application of an aglA gene in preparation of L-amino acid, and belongs to the technical field of biology. The application is the application of alpha-glucosidase or a substance for regulating and controlling the activity and / or content of the alpha-glucosidase in preparation of L-amino acid, and experiments prove that the aglA gene can remarkably improve the yield of the L-amino acid such as L-glutamic acid, L-lysine and L-threonine in a recombinant strain.

Described herein are compounds that reactivate acetylcholinesterase and associated methods of treating organophosphate poisoning.

A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

The invention relates to a framework based on a miR-30 framework, a construction method of the framework and application of the framework in RNAi (Ribonucleic Acid Interference). The skeleton construction method comprises the following steps: taking an existing shRNAmiR30 vector as a PCR (Polymerase Chain Reaction) template; the method comprises the following steps: designing two pairs of complementary overlapping primers of siRNA containing a target gene, namely primers F1 and R1 and primers F2 and R2, respectively performing amplification, and performing OE-PCR by taking the obtained P1 and P2 as templates and the primers F1 and R2 as upstream and downstream primers to obtain miR-OE. Furthermore, according to the construction method disclosed by the invention, reverse mutation of a stem-loop structure in a miR-OE skeleton and an EcoRI restriction enzyme cutting site is also carried out. The primers required to be synthesized in the miR-OE skeleton and miR-OE-EL construction method are short chains with the length of less than 60nt, the synthesis difficulty and cost are effectively reduced, and the primer design is more flexible; moreover, the interference efficiency of the miR-OE-EL skeleton on the target gene is obviously improved, and the miR-OE-EL skeleton can be well applied to preparation of shRNA drugs.

To provide an apple extract-containing composition that is less prone to sticking during a formulation process.SOLUTION: An apple extract-containing composition contains (A) an apple extract of 3 wt.% or more and 35 wt.% or less and (B) ang-khak, with a weight ratio of (A) to (B) (A / B) of 0.1 or more and 3.5 or less.SELECTED DRAWING: None

Provided are methods of administering ION582 for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in the cell or subject. In certain embodiments, the subject has Angelman syndrome (AS).

The present disclosure provides antibodies that specifically bind complement pathway component C1s The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-C1s antibodies; and host cells comprising the nucleic acids. The present disclosure provides compositions comprising the anti-C1s antibodies. The present disclosure provides methods of use of the anti-C1s antibodies.

The invention belongs to the technical field of singlet oxygen generation, and discloses an efficient singlet oxygen generation photosensitizer based on nitrogenous aliphatic ring size regulation and a theoretical calculation design method. A donor is introduced to the meso site of stilbene-BODIPY, the ring tension of the stilbene-BODIPY is effectively changed by adjusting the size of a nitrogen-containing ring, and the larger the ring tension is, the more unstable the molecule is, so that the oxidation potential of the donor is reduced, and the electron donating ability of the stilbene-BODIPY is further improved. The donor with stronger electron donating ability can obviously improve the intersystem crossing efficiency of photosensitizer molecules, thereby improving the quantum yield of singlet oxygen. According to the donor designed by the invention, the electron donating capability of the donor can be enhanced by adjusting the size of the nitrogen-containing aliphatic ring, the spin-orbit coupling is increased, and intersystem crossing is promoted. The calculation result shows that the photosensitizer has lower oxidation potential, smaller single triplet state energy gap, larger spin-orbit coupling coefficient and higher intersystem crossing rate, and shows more excellent potential in the field of singlet oxygen generation.

Recipe for a double microencapsulated powder, characterized in that the recipe comprises the following components in parts by weight: 5-60 parts by weight of core material of group A, 5-40 parts by weight of core material of group B, 5-16 parts by weight of protein shell material, 3-19 parts by weight of polysaccharide shell material, 0.1-2 parts by weight of immobilizing enzyme, 1-10 parts by weight of filler, 1-4 parts by weight of pH regulator and 0-2 parts by weight of antioxidant.